WO2006112541A1 - 自己乳化型製剤処方の設計方法 - Google Patents
自己乳化型製剤処方の設計方法 Download PDFInfo
- Publication number
- WO2006112541A1 WO2006112541A1 PCT/JP2006/308678 JP2006308678W WO2006112541A1 WO 2006112541 A1 WO2006112541 A1 WO 2006112541A1 JP 2006308678 W JP2006308678 W JP 2006308678W WO 2006112541 A1 WO2006112541 A1 WO 2006112541A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- emulsion
- test
- solvent
- turbidity
- evaluating
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 56
- 239000013583 drug formulation Substances 0.000 title claims abstract description 4
- 238000013461 design Methods 0.000 title abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 78
- 239000002904 solvent Substances 0.000 claims abstract description 72
- 238000009472 formulation Methods 0.000 claims abstract description 42
- 238000012360 testing method Methods 0.000 claims abstract description 42
- 238000007865 diluting Methods 0.000 claims abstract description 28
- 239000007787 solid Substances 0.000 claims abstract description 21
- 239000003085 diluting agent Substances 0.000 claims abstract description 19
- 239000007788 liquid Substances 0.000 claims abstract description 15
- 239000000839 emulsion Substances 0.000 claims description 70
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 31
- 229940079593 drug Drugs 0.000 claims description 28
- 230000008859 change Effects 0.000 claims description 25
- 238000011156 evaluation Methods 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 23
- 239000002245 particle Substances 0.000 claims description 22
- 238000010790 dilution Methods 0.000 claims description 21
- 239000012895 dilution Substances 0.000 claims description 21
- 238000000926 separation method Methods 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 18
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 10
- 238000005119 centrifugation Methods 0.000 claims description 10
- 238000003860 storage Methods 0.000 claims description 6
- 239000012085 test solution Substances 0.000 claims description 6
- 125000003158 alcohol group Chemical group 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 238000012854 evaluation process Methods 0.000 claims description 2
- 238000009529 body temperature measurement Methods 0.000 claims 1
- 229940126534 drug product Drugs 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000012216 screening Methods 0.000 abstract description 10
- 238000012377 drug delivery Methods 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract 4
- 239000004094 surface-active agent Substances 0.000 description 44
- -1 n-prononol Chemical compound 0.000 description 31
- 239000003921 oil Substances 0.000 description 22
- 235000019198 oils Nutrition 0.000 description 22
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 10
- 239000004359 castor oil Substances 0.000 description 9
- 235000019438 castor oil Nutrition 0.000 description 9
- 239000000470 constituent Substances 0.000 description 9
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 8
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 description 8
- 238000001035 drying Methods 0.000 description 7
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000004530 micro-emulsion Substances 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 229920001219 Polysorbate 40 Polymers 0.000 description 3
- 239000003655 absorption accelerator Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 235000019864 coconut oil Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 3
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 3
- 229940068977 polysorbate 20 Drugs 0.000 description 3
- 229940101027 polysorbate 40 Drugs 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- BKZCZANSHGDPSH-KTKRTIGZSA-N [3-(2,3-dihydroxypropoxy)-2-hydroxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)COCC(O)CO BKZCZANSHGDPSH-KTKRTIGZSA-N 0.000 description 2
- 229940124532 absorption promoter Drugs 0.000 description 2
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Polymers OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 2
- LLRANSBEYQZKFY-UHFFFAOYSA-N dodecanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCCCC(O)=O LLRANSBEYQZKFY-UHFFFAOYSA-N 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 229940093609 tricaprylin Drugs 0.000 description 2
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 2
- DJKGDNKYTKCJKD-BPOCMEKLSA-N (1s,4r,5s,6r)-1,2,3,4,7,7-hexachlorobicyclo[2.2.1]hept-2-ene-5,6-dicarboxylic acid Chemical compound ClC1=C(Cl)[C@]2(Cl)[C@H](C(=O)O)[C@H](C(O)=O)[C@@]1(Cl)C2(Cl)Cl DJKGDNKYTKCJKD-BPOCMEKLSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- AZLWQVJVINEILY-UHFFFAOYSA-N 2-(2-dodecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCOCCOCCO AZLWQVJVINEILY-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- NFIHXTUNNGIYRF-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCC NFIHXTUNNGIYRF-UHFFFAOYSA-N 0.000 description 1
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical group CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 1
- XERGTCWVYOKNAV-UHFFFAOYSA-N 2-methylpentane-1,2-diol Chemical compound CCCC(C)(O)CO XERGTCWVYOKNAV-UHFFFAOYSA-N 0.000 description 1
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- WPMWEFXCIYCJSA-UHFFFAOYSA-N Tetraethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCO WPMWEFXCIYCJSA-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- XLYOFNOQVPJJNP-DYCDLGHISA-N deuterium hydrogen oxide Chemical compound [2H]O XLYOFNOQVPJJNP-DYCDLGHISA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- HGVHMIAKUYLQLL-UHFFFAOYSA-N ethene;propane-1,2,3-triol Chemical compound C=C.OCC(O)CO HGVHMIAKUYLQLL-UHFFFAOYSA-N 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940100491 laureth-2 Drugs 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940040452 linolenate Drugs 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-M linolenate Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC([O-])=O DTOSIQBPPRVQHS-PDBXOOCHSA-M 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000001115 mace Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- NCYDRNOBBHFJHE-UHFFFAOYSA-N propane-1,2-diol;prop-1-ene Chemical compound CC=C.CC(O)CO NCYDRNOBBHFJHE-UHFFFAOYSA-N 0.000 description 1
- 229940116422 propylene glycol dicaprate Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 229940045845 sodium myristate Drugs 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- JUQGWKYSEXPRGL-UHFFFAOYSA-M sodium;tetradecanoate Chemical compound [Na+].CCCCCCCCCCCCCC([O-])=O JUQGWKYSEXPRGL-UHFFFAOYSA-M 0.000 description 1
- 238000002466 solution-enhanced dispersion by supercritical fluid Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/38—Diluting, dispersing or mixing samples
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/02—Investigating particle size or size distribution
- G01N15/0205—Investigating particle size or size distribution by optical means
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/06—Investigating concentration of particle suspensions
- G01N15/075—Investigating concentration of particle suspensions by optical means
Definitions
- the present invention relates to a method for designing a self-emulsifying formulation of a poorly water-soluble drug, and more specifically, a self-emulsifying formulation that enables the optimal formulation of a self-emulsifying formulation to be screened at high speed. Relates to the design method.
- Self-emulsifying drug delivery system consisting of drugs, oils, hydrophilic surfactants, lipophilic surfactants, absorption accelerators, auxiliary solvents, etc.
- S E D D S is a preparation prepared by uniformly mixing, dissolving or dispersing the above-mentioned components without water.
- S E D D S dissolves and disperses in water in the gastrointestinal tract after administration to form fine emulsions, thereby improving the absorbability of poorly water-soluble drugs and improving the variation in absorbability due to individual differences.
- the emulsification depends on the type and ratio of each component such as drugs, oils, hydrophilic surfactants, lipophilic surfactants, absorption accelerators, and auxiliary solvents. John's generation state and stability change discontinuously, so no theoretical design method is known. For this reason, in order to find a prescription that forms a good and stable emulsion, it was necessary to create many prescriptions with various types and ratios of each component and to perform screening by trial and error.
- oils, hydrophilic surfactants and lipophilic surfactants which are the main constituents of the SEDDS formulation, are generally viscous liquids at room temperature, or semisolid or solid. For this reason, the preparation of a small amount of the formulation for study had to be done manually. Even in that case, the weighing and mixing operations were extremely difficult, and there was a problem in throughput. In the early stages of drug development, there was a problem that the amount of drug that could be used for prescription studies was limited. Therefore, the types of each component used were limited empirically and evaluated with a limited number of prescriptions. In addition, if the types are not narrowed down, the number of prescriptions to be studied will increase dramatically, causing problems such as a prolonged study period, an increase in human labor and the amount of drugs used.
- a high-stressing LAS (Laboratory) is used to process a large number of samples in small quantities in an automated preparation analysis measurement system.
- oils, hydrophilic surfactants, lipophilic surfactants, etc. that are constituents of SEDDS are generally viscous liquids at room temperature, or are semi-solid or solid. It was difficult to dispense with HTFS and then mix, making it impossible to make HTFS.
- the HTFS system for intravenous formulation is known as a technology for preparing and evaluating an optimal formulation using a surfactant to solubilize poorly water-soluble compounds (TO 01/09391: Patent Document 1; W0 02/43765: Patent Document 2).
- SEDDS in order to correctly evaluate the state of the emulsion, it is essential that the additives in the formulation are uniformly mixed before being dispersed in water.
- the surfactant is diluted with water and mixed as an aqueous solution. Therefore, if this technology is applied to SEEDS, the surfactant does not sufficiently adsorb to the oil and an emulsion is formed. There was a problem that the original performance of the prescription could not be evaluated correctly.
- Non-patent Document 2 Nazzal, S., et al., 2002, Int. J. Pharm. 235, 247-265).
- Non-patent Document 3 Kawakami., K., et al., 2002, J. Controlled Release 81, 65-74
- Force Judgment between observers In addition to the variability, the throughput was low, and there was a problem with cost performance.
- the present inventor has intensively studied to achieve the above-mentioned problems, and has developed a system capable of continuously dispensing, mixing, and measuring a small amount of sample at a high speed in the evaluation of many SEDDS prescriptions.
- the present invention provides a method for designing a self-emulsifying formulation as shown below.
- a property evaluation step of the emulsion formed from the test mixture (e) force including a step of evaluating the particle size of the emulsion by turbidity measurement
- a property evaluation step of the emulsion formed from the test mixture (e) includes a step of evaluating the separation stability of the emulsion by measuring a change in turbidity before and after the centrifugation treatment.
- the present invention also provides a method for evaluating the following emulsion.
- a method for evaluating the properties of an emulsion comprising the step of evaluating the particle size of the emulsion by turbidity measurement.
- a method for evaluating the properties of an emulsion including a step of evaluating the separation stability of the emulsion by measuring the change in turbidity before and after the storage treatment.
- a method for evaluating the properties of an emulsion including the step of evaluating the separation stability of the emulsion by measuring the change in turbidity before and after the centrifugation.
- Figure 1 shows the measurement results of the turbidity of the obtained sample.
- Figure 2 shows the measurement results of the turbidity change after centrifugation in the obtained sample.
- Figure 3 shows the turbidity change after storage for 48 hours at 25 ° C in the obtained sample.
- a method comprising preparing a plurality of test mixtures by dispensing into a plurality of test containers so that each is added differently.
- a preferred embodiment of the present invention further includes: (c) removing the dilution solvent from the obtained plurality of test mixtures; (d) adding water to the obtained plurality of test mixtures; e) including a step of evaluating the properties of the emulsion formed from the plurality of test mixtures thus obtained.
- self-emulsifying preparation means a self-emulsifying drug composed of a poorly water-soluble drug, oil, hydrophilic surfactant, lipophilic surfactant, absorption accelerator, trapping solvent and the like. This refers to the Self-Emulsifying Drug Delivery System SEDDS (see Gursoy, NR, et al., 2004, Biomedicine & pharmacotherapy 58, 173-182, etc.).
- SEDDS Self-Emulsifying Drug Delivery System
- a constituent liquid that is viscous liquid at room temperature, or semi-solid or solid is dissolved in a diluent solvent to prepare a diluted solution containing the constituent.
- a constituent that is viscous liquid, semi-solid or solid at room temperature is a constituent that is added to a self-emulsifying formulation, without dilution with a diluent solvent. Hi. A substance that cannot be dispensed by a dispensing device such as a pet.
- Constants that can be dispensed with a dispensing device at room temperature are components that are added to self-emulsifying preparations, so that they can be dispensed with a dispensing device without diluting with a diluting solvent. Refers to a substance.
- components added to the self-emulsifying preparation include poorly water-soluble drugs (active ingredients), oils, lipophilic surfactants, hydrophilic surfactants, absorption promoters, auxiliary solvents, and the like.
- any one or more of active ingredients, oil, lipophilic surfactant and hydrophilic surfactant, which are the main constituents of SEDDS, are viscous liquid at room temperature, or semi-solid or When in solid form, such components are diluted with a diluting solvent such as lower alcohol, thereby enabling dispensing operations and thus automation. Therefore, the component diluted with the diluting solvent is not limited to one of the above components, and may be two or more or all components. In the present specification, “dilution” means dissolution or reduction in viscosity to such an extent that it can be dispensed by a dispensing apparatus (equipment) to be used.
- the components to be diluted and Z or the dilution solvent can be heated as necessary.
- the “dilution solvent” used in the present invention is not particularly limited as long as it can solubilize a viscous liquid, semi-solid or solid component (SEDDS component) to such an extent that it can be dispensed.
- a diluting solvent include alcohols (ethanol, n-prononol, isopropanol, pendino alcohol), dimethyl sulfoxide, N, N_dimethylacetamide, tetrahydrofuran, dioxane, dichloromethane, Examples include black mouth form and mixtures thereof.
- Preferred dilutions are those that do not interfere with the miscibility of the oil with the surfactant and do not cause the problem of poor emulsion formation when water is used as the solvent.
- the diluting solvent is preferably a lower alcohol having a polarity smaller than that of water.
- the “lower alcohol” means a linear or branched alcohol having 2 to 5 carbon atoms, such as methanol, ethanol, n-propanol, isopropanol, n-butanol, 2-butanol, 2-methyl.
- Illustrative examples include 1-propanol and 2-methyl-2-propanol.
- more preferred solvents are methanol, Tanol, n-propanol, isopropanol and mixtures thereof.
- a diluting solvent such as a lower alcohol is usually removed by evaporation, but it may remain slightly. Therefore, screening may result in selection of a prescription with low-grade alcohol remaining.
- a diluting solvent such as a lower alcohol
- ethanol it can be easily incorporated as a highly safe additive in the actual formulation. Therefore, it is unlikely to be a big problem in development. Therefore, it is particularly preferable to use ethanol as the diluting solvent among the lower alcohols of c 2 to c 5 .
- the amount of the dilution solvent added is not particularly limited as long as the target component can be diluted with a pipette.
- the diluent solvent is added so that the target component has a concentration of 5 to 80 w / w%, more specifically 25 to 60 w / w%.
- step (b) a combination test is performed so that the components contained in the diluted solution and the components other than the components are added with different types and amounts of the components.
- SEDDS is usually formulated with oil (O), hydrophilic surfactant (S), lipophilic surfactant (C o S), optionally absorption promoters, co-solvents Etc. are added.
- the oil (lipid) used here is not particularly limited.
- a fatty acid ester specifically, monopropylene propylene glycol mononitrate (NIKK0L Sefsol-218, Nikko Chemicals Co., Ltd., hereinafter referred to as “Sefsol-218”).
- NIKKOL Sefsol-228, Nikko Chemicals Co., Ltd. hereinafter referred to as “Sefsol-228”
- Tefsol-228 Propylene glycol dicaprate
- triacetin olive oil, sesame oil, da Oil, corn oil, rapeseed oil, castor oil, coconut oil, 'eucalyptus oil, etc .
- Miglyol 812 triglycerides such as tricaprylin, trilaurin
- polyglycerin fatty acid esters such as tetraglycerin mixed fatty acid esters.
- oils for example, “Sefsol-218”, “Sefsol-228”, Miglyol 812, or triglycerides such as tricaprylin and trilaurin are particularly useful as substances that can be dispensed without diluting with a diluting solvent. Can be mentioned.
- hydrophilic surfactant used here is 9.0 or more
- HLB hydrophilic surfactant
- polyoxyethylene lauryl ether laureth 2; BL_2, laureth 4.2; BL -4.2, Laures 9; BL-9
- mono coconut oil fatty acid polyoxyethylene (20) sorbitan NIKKOL TL-10, Nikko Chemicals Co., Ltd., hereinafter referred to as "Polysorbate 20”
- Polysorbate 40 Polysorbate 40
- Polysorbate 80 Labrasol konsuccinic acid D- ⁇ - ⁇ colyl polyethylene glycol 1000 (Vitamin E TPGS NF, EASTMAN
- TPGS NF Lauroyl polyoxyethylene glycerin (Gelucire 44/14, Gattefosse), polyoxyethylene hydrogenated castor oil 40 (HC0-40), polyoxyethylene hydrogenated castor oil 60 (HC0 -60), polyoxyethylene sorbitan monolaurate, polyoxyethylene sonolebitan monopalmitate, polyoxyethylene sonolebitan monooleate, and the like.
- the lipophilic surfactant (HLB value is less than 0 to less than 9.0) used here is not particularly limited.
- sorbitan monooleate NIKKOL SO-10V, Nikko Chemicals Co., Ltd., hereinafter “S0-10”
- Monopropyl propylene glycol CAPRY0L 90, Gattefosse, hereinafter referred to as “Capryol 90”
- propylene glycol monolaurate LAUR0GLYC0L 90, Gattefosse, hereinafter referred to as “Lauroglycol 90”
- propylene glycol laurate sorbitan monooleate
- LAUR0GLYC0L FCC, Gattefosse, hereinafter referred to as “uroglycol FCC”) polyoxyethylene (3) castor oil (NIKKOL C0-3, Nikko Chemicals Corporation, (Hereinafter referred to as “C0-3”), polyoxyethylene (10) castor oil (NIKKOL CO-10, Nikko Chemicals Corporation, hereinafter referred to as “C0-10”), decaglyceryl pentaoleate (NIKKOL Decaglyn 5-0V) , Nikko Chemicals Co., Ltd., hereinafter referred to as “Decaglyn 5-0”), diglyceryl monooleate (NIKKOL DGM0-CV, Nikko Chemicals Co., Ltd., hereinafter referred to as I DGM0-C), hexaglyseryl dioleate (PULUROL 0LEIQUE 497, Gattefosse, hereinafter referred to as “Pulurol oleique 497”), polyoxyethylene g
- scavenging solvent such as acetic acid, diethylanolamine, triethanolamine, ethylenediamine, monoethanolamine, N, N-dimethylacetamide, etc. can be blended.
- propylene glycol or polyethylene glycol is used as an auxiliary solvent, it is preferable to dilute with a diluent solvent.
- oils, surfactants, and additives that can be used in the present invention can refer to known literatures, reference books, etc. (13th revised Japanese Pharmacopoeia; Japanese Pharmacopoeia Pharmaceutical Standards 1997; Pharmaceuticals) Additives Standard 1998; Food Additives Official Version 7; Cosmetics Material Standards New Edition; Cosmetic Ingredients Standards; Quasi-drug Raw Material Standards; United States Pharmacopeia 24; British Pharmacopeia 2000; European
- a diluted solution based on the method in step (a) above, and use a dispensing device (equipment). Dispense into multiple test containers. Other components that can be dispensed without dilution with other components of the SEDDS process, or after diluting with a diluting solvent as necessary, multiple test containers can be prepared using a dispensing device. Dispense into W.
- the order of dispensing each component is not particularly limited as long as the SEDDS formulation can be prepared, but usually (1) active ingredient, (2) oil, (3) hydrophilic surfactant, (4) Dispense into each test container in the order of lipophilic surfactant.
- Examples of the dispensing device include pipettes and LAS pipettes.
- Examples of test containers used here include test tubes and plates that can contain multiple test substances (eg, 96-well plates, 384-well plates).
- commercially available LAS can be preferably used.
- GENESIS Workstation 200 manufactured by TECA
- MultiPROBE II plus manufactured by Perkin Elmer
- LAS it is possible to automatically dispense multiple prescriptions with a small amount of sample at the same time.
- the plurality of dispensed components can be more easily mixed.
- LAS enables dispensing of a low volume, which can reduce the amount of drug used.
- Each of the above components is adjusted to an appropriate different ratio and dispensed into each test container.
- the diluted solvent added in step (a) is usually removed.
- Such removal of the diluting solvent is not particularly limited, but is usually performed by drying under reduced pressure.
- ethanol used as a diluting solvent, it can be removed by drying at room temperature to 40 ° C for about 4 to 10 hours (for example, 1 kg) under reduced pressure.
- a plurality of candidate formulations for emulsion formulations can be prepared by removing the dilution solvent from each test mixture contained in each test container. Obtained in this way Candidate prescriptions for emulsion formulations will be evaluated in the next step to determine whether they are suitable as self-emulsifying products.
- the self-emulsifying preparation is a preparation in which the above-mentioned constituents are uniformly mixed, dissolved or dispersed in a state not containing water.
- water, gastric juice, a mixture of these, etc. It is designed to dissolve and disperse to form fine emulsions. Therefore, in order to evaluate whether the candidate formulation of the emulsion formulation prepared as described above is appropriate, first, water or a test solution is added to form an emulsion.
- test liquid means a liquid that can self-emulsify SEEDS. (JP 2) etc.) Artificial gastric juice diluted with water is used. The amount of water or test solution added can be changed appropriately according to the type and amount of each component.
- each test container 5 to 20 times the amount of water or test solution is added to the test mixture. Added. After adding water or test solution, it is usually stirred to form an emulsion. Stirring is not limited to this. For example, the stirring is performed at 500 to 2000 rpm for about 20 seconds to 1 minute.
- the properties of the emulsion formed as described above are evaluated. Since the indices representing the physical properties of the emulsion are particle size and separation of the emulsion which is physical stability, these properties are usually evaluated.
- a method for evaluating such properties a conventionally known method can be used. For example, a dynamic light scattering method (hereinafter referred to as “D L S”) can be used as a method for measuring the particle diameter.
- D L S dynamic light scattering method
- a method of evaluating turbidity with a turbidimeter can also be used as a parameter reflecting the particle size.
- the present inventor has found that the particle diameter of the emulsion formed by SEDDS can be rapidly evaluated by measuring turbidity using a microplate absorptiometer. Further, the present inventor has found that the separation stability of SEDDS can be evaluated by a change in turbidity. Therefore, in a preferred embodiment of the present invention, as an evaluation method for the emulsion,
- the evaluation is performed by combining the evaluation methods (e-1) to (e-3), and the optimal formulation is determined based on the results. .
- the particle size evaluation method of the present invention a small amount of drug It is possible to evaluate the particle size of multi-formulation SEDDS quickly and at low cost with the amount used.
- the change in turbidity before and after the preservation of the emulsion or the change in turbidity before and after the centrifugation of the emulsion is measured.
- the emulsion prepared as described above is stored for 6 hours or more and 72 hours or less under the condition of 1 ° C or more and 40 ° C or less, and the change in turbidity before and after that is evaluated to separate SEDDS. It is possible to evaluate the presence or absence of
- the emulsion prepared for evaluation in a shorter time under more severe conditions can be subjected to centrifugation.
- centrifugation for example, from 1,500
- the separated state includes (1) a case where the cream layer and the transparent layer are separated, and (2) a case where the layer is separated into the transparent layer and the transparent layer. Such separation can also be evaluated by turbidity. In some cases, it is also possible to detect the precipitation of drugs and the generation of insoluble substances due to changes in the composition of prescription components. As mentioned above, turbidity has the advantage that it can be evaluated quickly and at low cost with a low volume sample.
- NIKKOL HC0-40 polyoxyethylene (40) hydrogenated castor oil (NIKKOL HC0-40 (medicine), Nikko Chemicals Co., Ltd., hereinafter referred to as “HC0-40”) Chain fatty acid glycerides (0D0-C, Nissin Oilio Group Co., Ltd., hereinafter referred to as “MCT”) were used.
- the prescription is a table
- the weight corresponding to HC0-40 300 i L was measured directly into the vial. After dispensing 300 ⁇ ⁇ of water, stir Stir. Subsequently, ⁇ 150 ⁇ was dispensed. However, since the HC0-40 aqueous solution was gelled, it was difficult to uniformly stir.
- Example 1 Sample preparation using ethanol as a diluting solvent
- HC0-40 was heated and melted, and then dissolved in ethanol to 50 w / w%. 600 (300 L as HC0-40) and MCT150 ⁇ L were dispensed into vials using a pipette. Stir for homogenization. Then, it was dried for 12 hours in a vacuum dryer, and 2400 / L of water was added thereto to prepare Sample 3.
- Comparative Example 2 As described in Comparative Example 1, pipetting was not possible when no dilution solvent was used. Even in Comparative Example 2 where water was used as the diluent solvent, it was difficult to dispense HC0-40 with a pipet. In Comparative Examples 1 and 2,
- HC0-40 could be dispensed with a pipette and could be dispensed easily and quickly. It was also easily and quickly mixed with MCT.
- Comparative Example 1 Comparative Example 2, Comparative Example 2, Samples 1 to 3 of Invention 1 was visually observed.
- the same three samples were dispensed into 200 microplates, and the turbidity at 650 nm was measured with an absorptiometer (SpectraMax 190, Molecular device). Sample 1 without dilution solvent was used as a control.
- Table 2A Table 2 A
- M E micro-emulsion
- MWE White Micro Emulsion
- ME mixture of the enlarged emulsion and ME.
- Mac E Macromarsion
- Macromarsion shows a cloudy state with an opaque appearance due to the formation of 1 ⁇ order emulsion.
- ethanol was used as the diluent solvent, and a sample without drying treatment was prepared as follows. After HC0-40 was melted by heating, it was dissolved in ethanol so as to be 50 w / w%. 600 ⁇ (300 L as HC0-40) and MCT150 / L were dispensed into a pial bottle using a pipette. Stirred for homogenization. To this, 2400 ⁇ water was added to make Sample 5.
- Test example 3 Evaluation of the effect of dilution solvent on residual solvent
- Example 3 Dispensing accuracy Using a surfactant diluted to 50 w / w% with ethanol, dispensing accuracy in LAS (GENESIS Workstation 200, TECAN) was evaluated. The setting value for the dispensing volume was 200 L. '
- polyoxyethylene (2) lauryl ether NIKK0L BL-2, Nikko Chemicals Co., Ltd., hereinafter referred to as “BL-2”
- polyoxyethylene (4.2) lauryl ether NIKKOL BL-4.
- BL-4.2 Nikko Chemicals Co., Ltd., hereinafter referred to as “BL-4.2”
- polyoxyethylene (9) lauryl ether NIKKOL BL-9EX, Nikko Chemicals Co., Ltd., hereinafter referred to as “BL-9”
- Monopalmichi Polyoxyethylene (20) sorbitan NIKKOL TP-10V, Nikko Chemicals Co., Ltd., hereinafter referred to as “Polysorbate 40J”
- Polyoxyethylene (20) sorbitan monooleate NIKKOL TO-10MV, Nikko Chemicals Co., Ltd., hereinafter referred to as rPolysorbate 80J)
- Powered polyoxyethylene (8) glycerin (LABMS0L, Gattefosse, hereinafter referred to as “Labrasol”); HC0-40 Polyoxyethylene (60) hydrogenated castor oil (NIKKOL HC0 - 6 Fei (pharmaceutical) Nikko Chemicals Co., hereinafter - referred to as “HC0 60”) was used.
- oils and surfactants were dispensed into 96-well plates using LAS (GENESIS Workstation 200, TECA).
- the surfactant was used as a 50 v / v% ethanol solution.
- HC0-60 was prepared to 5: 5, 4: 6, 3: 7, 2: 8, 1: 9).
- the oil and surfactant were dispensed in a total of 50 SEDDS.
- Nilubadipine Kongo Pharmaceutical Co., Ltd., hereinafter referred to as “Nil”) was used as a model compound.
- the drug Since the drug cannot be directly dispensed as a powder, it was prepared in a mg / mL ethanol solution and added to 4 mg / mL Ni in 1 mL SEDDS. The mixture of drug, oil, hydrophilic surfactant and lipophilic surfactant was stirred to homogenize. Then, it was vacuum-dried overnight (12 hours or more), and ethanol as a diluting solvent was evaporated. Distilled water (450 / iL) was added to the dried mixture, and the mixture was stirred as a sample.
- hydrophilic surfactants BL-2, BL-4.2, BL-9, mono coconut oil fatty acid polyoxyethylene (20) sorbitan (NIKKOL TL-10, Nikko Chemicals Co., Ltd., hereinafter referred to as “Polysorbate 20”), Polysorbate 40 , Polysorbate 80, Labrasol, succinic acid D- ⁇ -tupheryl polyethylene glycol 1000
- TPGS NF (Vitamin E TPGS NF, 'EASTMAN Chemical Co., hereinafter referred to as "TPGS NF")
- Lau mouth inoposito aged xylene ethylene glycerol (Gelucire 44/14, Gattefosse Co.), HC0-40, HC0-60 were used.
- sorbitan monooleate NIKKOL SO-10V, Nikko Chemicals Co., Ltd., hereinafter referred to as “S0-10”
- monopropylene propylene glycol CAPRY0L 90, Gattefosse, Inc., hereinafter referred to as Capryol 90
- Propylene glycol monolaurate LAUR0GLYC0L 90, Gattefosse, hereinafter referred to as “Lauroglycol 90”
- Lauroglycol FCC polyoxyethylene (3) castor oil
- C0-3 polyoxyethylene (10) castor Oil
- co-ioj polyoxyethylene (10) castor Oil
- Decaglyn 5-0 diglyceryl monooleate
- DGM0-C diglyceryl monooleate
- PULUROL OLEIQUE 497 Gattefosse
- Polyoxyethylene glycerol oleate (6) LABRAFIL M 1944 CS, Gattefosse, hereinafter referred to as “Labrafil 1944”
- Polyoxyethylene glycerin linolenate (6) LABRAFIL M 2125 CS, Gattefosse, “Labrafil 2125”.
- a sample was poured into a microplate for 200 minutes, and the turbidity at 650 nm was measured with a spectrophotometer (SpectraMax 190, Molecular device Co., Ltd.) for type discrimination by particle size. The results are shown in Fig. 1.
- a formulation with low turbidity means that the particle size of the emulsion is small.
- a prescription with a turbidity of 0.3 or less is M E
- a 96-well plate dispensed with sample 200 ii L was stored at 25 ° C for 48 hours, and the change in turbidity (650 nm) was measured before and after that. The results are shown in Fig. 3. As the physical stability is good, the change in turbidity is 0! A prescription of ⁇ 0.1 was selected.
- an HTFS system for quickly preparing and evaluating a SEDDS formulation containing a sparingly soluble active ingredient and the like at a low cost. Therefore, according to the present invention, there is an advantage that an optimal SEDDS recipe can be rapidly developed.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06732334.5A EP1879013A4 (en) | 2005-04-20 | 2006-04-19 | METHOD FOR CONSTRUCTING SELF-VULGATED DRUG ORMULATIONS |
US11/911,568 US20090124670A1 (en) | 2005-04-20 | 2006-04-19 | Method for designing formulation of self-emulsifying preparation |
JP2007528214A JP5250258B2 (ja) | 2005-04-20 | 2006-04-19 | 自己乳化型製剤処方の設計方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-122347 | 2005-04-20 | ||
JP2005122347 | 2005-04-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006112541A1 true WO2006112541A1 (ja) | 2006-10-26 |
Family
ID=37115237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/308678 WO2006112541A1 (ja) | 2005-04-20 | 2006-04-19 | 自己乳化型製剤処方の設計方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20090124670A1 (ja) |
EP (1) | EP1879013A4 (ja) |
JP (1) | JP5250258B2 (ja) |
WO (1) | WO2006112541A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013544367A (ja) * | 2010-12-06 | 2013-12-12 | ラモット アット テル−アビブ ユニバーシティー リミテッド | 薬物検出のための方法およびキット |
WO2015071841A1 (en) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
CN107670045A (zh) * | 2017-11-17 | 2018-02-09 | 天津科技大学 | 一种具有抗光敏作用的药物赋形剂及其制备方法 |
WO2018124162A1 (ja) | 2016-12-28 | 2018-07-05 | 中外製薬株式会社 | 化合物の膜透過性を改善するための自己乳化型製剤 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115715765A (zh) * | 2021-08-24 | 2023-02-28 | 江苏万邦生化医药集团有限责任公司 | 一种悬浮片剂 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07126154A (ja) * | 1993-10-29 | 1995-05-16 | Terumo Corp | 難水溶性医薬品含有医薬製剤 |
JPH0873361A (ja) * | 1994-07-07 | 1996-03-19 | Kirin Brewery Co Ltd | 抗腫瘍薬物の用時調合型セット製剤 |
JP2004520359A (ja) * | 2001-01-18 | 2004-07-08 | ファルマシア・コーポレーション | 薬物の結晶化が低減された性質を有する医薬組成物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7030155B2 (en) * | 1998-06-05 | 2006-04-18 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
JP4429590B2 (ja) * | 2002-02-08 | 2010-03-10 | 株式会社協和ウェルネス | ユビキノン含有水可溶性組成物 |
FR2836231B1 (fr) * | 2002-02-21 | 2004-07-23 | Gattefosse Holding | Procede d'elaboration d'un diagramme ternaire d'un melange et installation pour la mise en oeuvre du procede |
AU2003285143A1 (en) * | 2002-11-04 | 2004-06-07 | Transform Pharmaceuticals, Inc. | Analysis of pharmaceutical solubility and stability |
EP1498143A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids |
-
2006
- 2006-04-19 JP JP2007528214A patent/JP5250258B2/ja not_active Expired - Fee Related
- 2006-04-19 EP EP06732334.5A patent/EP1879013A4/en not_active Withdrawn
- 2006-04-19 WO PCT/JP2006/308678 patent/WO2006112541A1/ja active Application Filing
- 2006-04-19 US US11/911,568 patent/US20090124670A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07126154A (ja) * | 1993-10-29 | 1995-05-16 | Terumo Corp | 難水溶性医薬品含有医薬製剤 |
JPH0873361A (ja) * | 1994-07-07 | 1996-03-19 | Kirin Brewery Co Ltd | 抗腫瘍薬物の用時調合型セット製剤 |
JP2004520359A (ja) * | 2001-01-18 | 2004-07-08 | ファルマシア・コーポレーション | 薬物の結晶化が低減された性質を有する医薬組成物 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1879013A4 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013544367A (ja) * | 2010-12-06 | 2013-12-12 | ラモット アット テル−アビブ ユニバーシティー リミテッド | 薬物検出のための方法およびキット |
WO2015071841A1 (en) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
WO2018124162A1 (ja) | 2016-12-28 | 2018-07-05 | 中外製薬株式会社 | 化合物の膜透過性を改善するための自己乳化型製剤 |
CN107670045A (zh) * | 2017-11-17 | 2018-02-09 | 天津科技大学 | 一种具有抗光敏作用的药物赋形剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1879013A4 (en) | 2014-05-21 |
EP1879013A1 (en) | 2008-01-16 |
US20090124670A1 (en) | 2009-05-14 |
JPWO2006112541A1 (ja) | 2008-12-11 |
JP5250258B2 (ja) | 2013-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Matsaridou et al. | The influence of surfactant HLB and oil/surfactant ratio on the formation and properties of self-emulsifying pellets and microemulsion reconstitution | |
Singh et al. | Self-emulsifying drug delivery systems (SEDDS): formulation development, characterization, and applications | |
Kollipara et al. | Pharmacokinetic aspects and in vitro–in vivo correlation potential for lipid-based formulations | |
Parmar et al. | Study of cosurfactant effect on nanoemulsifying area and development of lercanidipine loaded (SNEDDS) self nanoemulsifying drug delivery system | |
Kohli et al. | Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability | |
Abdalla et al. | Preparation and characterization of a self-emulsifying pellet formulation | |
Pratiwi et al. | Self-nanoemulsifying Drug Delivery System (Snedds) for topical delivery of mangosteen peels (Garcinia mangostana L.,): Formulation design and in vitro studies | |
Rahman et al. | Formulation optimization and in vitro characterization of sertraline loaded self-nanoemulsifying drug delivery system (SNEDDS) for oral administration | |
Akhter et al. | Formulation and development of CoQ10-loaded s-SNEDDS for enhancement of oral bioavailability | |
Bora et al. | Formulation and Evaluation of Self microemulsifying drug delivery systems of low solubility drug for enhanced solubility and dissolution | |
WO2006112541A1 (ja) | 自己乳化型製剤処方の設計方法 | |
Duc Hanh et al. | Development of phyllanthin-loaded self-microemulsifying drug delivery system for oral bioavailability enhancement | |
Ahmad et al. | Construction of pseudoternary phase diagram and its evaluation: development of self-dispersible oral formulation | |
Swain et al. | Pharmaceutical drug delivery systems and vehicles | |
Shukla et al. | Formulation and evaluation of oral self microemulsifying drug delivery system of candesartan cilexetil | |
Kamboj et al. | Lipid based delivery of Efavirenz: an answer to its erratic absorption and food effect | |
Suhery et al. | Development and characterization of self-nanoemulsifying drug delivery system (SNEDDS) formulation for enhancing dissolution of fenofibric acid | |
Patel et al. | Development of Solid SEDDS, II: application of Acconon® C-44 and Gelucire® 44/14 as solidifying agents for self-emulsifying drug delivery systems of medium chain triglyceride. | |
Ke et al. | Formulation design and in vitro evaluation of berberine-loaded self-nanoemulsifying drug delivery system | |
Prajapati et al. | In vitro dispersion test that could serve as a predictive method for assessing performance of lipid-based drug delivery systems. | |
Misal et al. | Review on: New approaches in self micro-emulsifying drug delivery system | |
Benameur | Liquid and semi-solid formulations for enhancing oral absorption | |
Nicholas et al. | Ibuprofen selfemulsifying drug delivery system | |
Shah et al. | Self-microemulsifying system | |
Patel et al. | Quality by design approach to the development of self-microemulsifying systems for oral delivery of teriflunomide: design, optimization, and: in vitro: and: in vivo: evaluation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007528214 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11911568 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2006732334 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006732334 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006732334 Country of ref document: EP |